Company DescriptionHisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.

How the Company Makes Money

Hisamitsu Pharmaceutical Co Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Breakdown
Income Statement		Total Revenue
150.13B	141.71B	128.33B	120.19B	114.51B	140.99B
	Gross Profit
86.76B	78.97B	72.70B	70.07B	69.17B	87.60B
	EBIT
14.12B	13.17B	11.60B	9.34B	10.67B	22.73B
	EBITDA
22.94B	24.37B	16.55B	13.66B	14.75B	26.98B
	Net Income Common Stockholders
15.52B	13.97B	11.74B	9.66B	9.25B	18.69B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
26.93B	125.32B	136.87B	142.43B	136.00B	141.93B
	Total Assets
193.55B	328.78B	313.92B	302.86B	299.86B	307.40B
	Total Debt
18.81B	2.10B	2.29B	2.46B	1.60B	1.77B
	Net Debt
-8.13B	-110.36B	-119.86B	-126.83B	-112.65B	-105.28B
	Total Liabilities
62.58B	61.70B	55.51B	47.98B	46.06B	56.66B
	Stockholders Equity
130.09B	264.88B	256.36B	253.16B	252.29B	249.27B
Cash Flow		Free Cash Flow
-892.50M	5.15B	4.82B	15.01B	1.90B	23.67B
	Operating Cash Flow
4.13B	18.19B	12.73B	19.20B	5.29B	27.39B
	Investing Cash Flow
2.12B	-2.51B	-23.87B	-13.06B	7.82B	-17.23B
	Financing Cash Flow
-6.17B	-16.69B	-14.69B	-15.19B	-7.19B	-11.73B

Hisamitsu Pharmaceutical Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HTSUF		$2.24B	16.67	7.90%	1.81%	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
DNPUF		$2.21B	15.17	13.50%	―	―	―
TRXPF		$1.23B	28.25	4.56%	2.13%	―	―
TSMRF		$1.76B	10.69	11.16%	3.01%	―	―
4516	75 Outperform	¥238.03B	7.31		3.51%	8.08%	25.92%
4887	69 Neutral	¥174.66B	9.49		3.02%	-3.69%	76.69%

* Healthcare Sector Average

Performance Comparison

HTSUF

Hisamitsu Pharmaceutical Co

32.30

8.48

35.60%

DNPUF

Sumitomo Dainippon Pharma Co

5.58

3.32

146.90%

TRXPF

Torii Pharmaceutical Co

36.62

13.56

58.80%

TSMRF

Tsumura & Co

29.95

4.97

19.90%

JP:4516

Nippon Shinyaku Co., Ltd.

3,534.00

483.74

15.86%

JP:4887

SAWAI GROUP HOLDINGS Co., Ltd.

1,780.00

-107.89

-5.71%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.